GeneDx Investors Face August Deadline in Securities Fraud Lawsuit

The litigation, captioned Taher Basma v. GeneDx Holdings Corp., centers on allegations that the genetic testing firm misled shareholders regarding the viability of its $51 million acquisition of Fabric Genomics. While GeneDx originally touted the deal as a transformative move to secure high-leverage, recurring revenue through AI-driven genomic interpretation, the complaint claims these statements lacked a reasonable basis and concealed significant operational failures within Fabric.

The underlying concerns intensified on May 4, 2026, when GeneDx reported its first-quarter results. The company disclosed a sharp decline in adjusted gross margins, lowered earnings projections, and an impairment loss of $31.3 million tied directly to the Fabric acquisition—nearly the entire amount of the initial cash outlay. Following the announcement, GeneDx shares plummeted by more than 49%. Investors seeking to recover losses or participate in the class action are encouraged to contact Kessler Topaz Meltzer & Check, LLP, which is coordinating legal representation for affected parties.